Merck & Co Inc · 8-K · For 10/18/02 · EX-99.B
Filed On 10/18/02 4:14pm ET · SEC File 1-03305 · Accession Number 950123-2-9793
As Of Filer Filing As/For/On Docs:Pgs Issuer Agent
10/18/02 Merck & Co Inc 8-K{7,9} 10/18/02 3:23 Bowne of NY City...01/FA
Current Report · Form 8-K
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 8-K Current Report 3 11K
2: EX-99.A Press Release 13 49K
3: EX-99.B Certain Supplemental Information 7 28K
EX-99.B · Certain Supplemental Information
| EX-99.B | 1st Page of 7 | TOC | Top | Previous | Next | Bottom | Just 1st |
|---|
Exhibit 99(b)
MERCK & CO., INC.
GROSS PRODUCT SALES DETAIL
[Download Table]
3Q `02 vs. 3Q `01
--------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
-------------------- ----- ----- ---- ---- ------- -------
VIOXX 2% $ 810 -4% $ 600 24% $210
ARCOXIA N/M 10 N/M -- N/M 10
VASOTEC / VASERETIC -24% 185 N/M (10) -9% 195
PRINIVIL / PRINZIDE -38% 165 -43% 140 25% 25
COZAAR / HYZAAR 8% 585 -5% 260 23% 325
MEVACOR -50% 55 -56% 40 -25% 15
ZOCOR 11% 1,925 6% 1,340 24% 585
AGGRASTAT 0% 25 0% 15 N/M 10
SINGULAIR 9% 380 0% 270 38% 110
MAXALT 36% 95 25% 75 100% 20
PROPECIA 0% 55 20% 30 -17% 25
PROSCAR 18% 165 36% 95 0% 70
PRIMAXIN 11% 155 38% 55 0% 100
INVANZ N/M 5 N/M -- N/M 5
CANCIDAS N/M 30 N/M 20 N/M 10
PEPCID -57% 15 -75% 5 -33% 10
FOSAMAX 11% 500 -2% 315 42% 185
CRIXIVAN/STOCRIN -39% 70 -69% 20 0% 50
TIMOPTIC/TIMOPTIC XE -20% 40 -67% 5 0% 35
TRUSOPT/COSOPT 15% 115 22% 55 9% 60
HEPATITIS VACCINES -15% 85 -22% 70 50% 15
VIRAL VACCINES -9% 145 -7% 140 -50% 5
OTHER VACCINES N/M 55 N/M 45 N/M 10
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
Exhibit 99(b)
MERCK & CO., INC.
GROSS PRODUCT SALES DETAIL
[Enlarge/Download Table]
9 MONTHS 2002 OVER 2001
------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
---------------------- ----- ----- ---- ---- ------- -------
VIOXX 15% $2,305 12% $1,715 24% $ 590
ARCOXIA N/M 20 N/M -- N/M 20
VASOTEC / VASERETIC -28% 580 N/M -- -16% 580
PRINIVIL / PRINZIDE -12% 830 -12% 765 -7% 65
COZAAR / HYZAAR 12% 1,610 16% 740 9% 870
MEVACOR -51% 190 -56% 145 -25% 45
ZOCOR 12% 5,155 11% 3,555 12% 1,600
AGGRASTAT -6% 80 -27% 40 33% 40
SINGULAIR 7% 1,100 1% 805 31% 295
MAXALT 15% 235 9% 180 38% 55
PROPECIA -3% 155 -12% 75 7% 80
PROSCAR 0% 410 0% 210 0% 200
PRIMAXIN -2% 430 4% 135 -5% 295
INVANZ N/M 10 N/M 5 N/M 5
CANCIDAS N/M 70 N/M 45 N/M 25
PEPCID -86% 45 -93% 20 -50% 25
FOSAMAX 32% 1,700 30% 1,220 37% 480
CRIXIVAN/STOCRIN -33% 225 -43% 85 -24% 140
TIMOPTIC/TIMOPTIC XE -24% 125 -56% 20 -13% 105
TRUSOPT/COSOPT 8% 325 7% 155 10% 170
HEPATITIS VACCINES -17% 225 -18% 200 0% 25
VIRAL VACCINES 4% 440 8% 425 -50% 15
OTHER VACCINES N/M 95 N/M 65 N/M 30
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
Exhibit 99(b)
MERCK & CO., INC.
NET PRODUCT SALES DETAIL
[Enlarge/Download Table]
3Q `02 vs. 3Q `01
-----------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
-------------------- ----- ----- ---- ---- ------- -------
VIOXX 3% $ 755 -3% $ 545 24% $ 210
ARCOXIA N/M 10 N/M -- N/M 10
VASOTEC / VASERETIC -24% 185 N/M (10) -9% 195
PRINIVIL / PRINZIDE -24% 80 -35% 55 25% 25
COZAAR / HYZAAR 8% 550 -8% 225 23% 325
MEVACOR -33% 30 -40% 15 -25% 15
ZOCOR 9% 1,470 1% 885 24% 585
AGGRASTAT -20% 20 -33% 10 N/M 10
SINGULAIR 11% 350 2% 240 38% 110
MAXALT 23% 80 9% 60 N/M 20
PROPECIA 0% 55 20% 30 -17% 25
PROSCAR 19% 155 42% 85 0% 70
PRIMAXIN 11% 150 43% 50 0% 100
INVANZ N/M 5 N/M -- N/M 5
CANCIDAS N/M 30 N/M 20 N/M 10
PEPCID -50% 10 -100% -- -33% 10
FOSAMAX 9% 455 -5% 270 37% 185
CRIXIVAN/STOCRIN -41% 65 -75% 15 0% 50
TIMOPTIC/TIMOPTIC XE -20% 40 -67% 5 0% 35
TRUSOPT/COSOPT 11% 105 13% 45 9% 60
HEPATITIS VACCINES -7% 65 -17% 50 N/M 15
VIRAL VACCINES -6% 145 -3% 140 N/M 5
OTHER VACCINES N/M 80 N/M 70 N/M 10
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
Exhibit 99(b)
MERCK & CO., INC.
NET PRODUCT SALES DETAIL
[Enlarge/Download Table]
9 MONTHS 2002 OVER 2001
-----------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
------------------- ----- ----- ---- ---- ------- -------
VIOXX 17% $2,145 14% $1,555 24% $ 590
ARCOXIA N/M 20 N/M -- N/M 20
VASOTEC / VASERETIC -27% 580 -100% -- -16% 580
PRINIVIL / PRINZIDE -12% 470 -13% 405 -7% 65
COZAAR / HYZAAR 10% 1,505 11% 635 9% 870
MEVACOR -58% 90 -71% 45 -25% 45
ZOCOR 8% 3,840 5% 2,240 12% 1,600
AGGRASTAT -6% 75 -30% 35 33% 40
SINGULAIR 5% 995 -3% 700 31% 295
MAXALT 14% 205 7% 150 38% 55
PROPECIA -3% 155 -12% 75 7% 80
PROSCAR -3% 385 -5% 185 0% 200
PRIMAXIN -5% 410 -4% 115 -5% 295
INVANZ N/M 10 N/M 5 N/M 5
CANCIDAS N/M 65 N/M 40 N/M 25
PEPCID -85% 40 -93% 15 -50% 25
FOSAMAX 29% 1,555 26% 1,075 35% 480
CRIXIVAN/STOCRIN -33% 215 -44% 75 -24% 140
TIMOPTIC/TIMOPTIC XE -22% 125 -50% 20 -13% 105
TRUSOPT/COSOPT 5% 305 0% 135 10% 170
HEPATITIS VACCINES -19% 170 -22% 145 0% 25
VIRAL VACCINES 4% 430 8% 415 N/M 15
OTHER VACCINES N/M 165 N/M 135 N/M 30
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
Exhibit 99(b)
MERCK & CO., INC.
CONSOLIDATED
THIRD QUARTER
[Download Table]
3Q `02 3Q `01 % CHG.
------ ------ ------
TOTAL SALES $ 12,892.9 $ 11,919.6 8%
---------- ----------
TOTAL COSTS, EXPENSES, & OTHER $ 10,201.6 $ 9,136.5
---------- ----------
Materials & Production 8,080.1 7,082.8
Marketing & Administrative 1,562.7 1,525.3
Research & Development 676.9 590.3
Equity Income From Affiliates (188.7) (164.1)
Other (Income)/Expense, Net 70.6 102.2
PRE-TAX INCOME $ 2,691.3 $ 2,783.1
TAXES $ 807.3 $ 834.9
TAX RATE 30.0% 30.0%
NET INCOME $ 1,884.0 $ 1,948.2 -3%
EPS - ASSUMING DILUTION $ 0.83 $ 0.84 -1%
AVG. # SHARES - ASSUMING DILUTION 2,265.9 2,312.4
[Download Table]
3Q `02 % CHG. VOL PX FX
------- ------- ---- ---- ----
TOTAL SALES $12,890 8% 0 7 1
------- ---- ---- ---- ----
Total Pharmaceutical Sales 5,515 1% -2 2 1
------- ---- ---- ---- ----
U.S. 3,390 -6% -12 6 0
Foreign 2,125 14% 14 -3 3
Other Medco Sales 7,375 14%
Exhibit 99(b)
MERCK & CO., INC.
CONSOLIDATED
NINE MONTHS YEAR TO DATE
[Download Table]
2002 2001 % CHG.
---------- ---------- ----------
TOTAL SALES $ 37,871.9 $ 35,157.8 8%
---------- ----------
TOTAL COSTS, EXPENSES, & OTHER $ 30,358.1 $ 27,413.7
---------- ----------
Materials & Production 24,353.5 21,334.1
Marketing & Administrative 4,505.3 4,669.0
Research & Development 1,838.4 1,740.0
Equity Income From Affiliates (550.7) (557.8)
Other (Income)/Expense, Net 211.6 228.4
PRE-TAX INCOME $ 7,513.8 $ 7,744.1
TAXES $ 2,254.1 $ 2,323.2
TAX RATE 30.0% 30.0%
NET INCOME $ 5,259.7 $ 5,420.9 -3%
EPS - ASSUMING DILUTION $ 2.31 $ 2.33 -1%
AVG. # SHARES - ASSUMING DILUTION 2,281.0 2,329.1
[Download Table]
2002 % CHG. VOL PX FX
------- ----- ---- ---- ----
TOTAL SALES $37,870 8% 2 6 0
------- ---- ---- ---- ----
Total Pharmaceutical Sales 15,570 -1% 0 0 -1
------- ---- ---- ---- ----
U.S. 9,690 -4% -6 2 0
Foreign 5,880 4% 9 -2 -3
Other Medco Sales 22,300 15%
Exhibit 99(b)
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2002
================================================================================
OTHER (INCOME)/EXPENSE, NET
[Download Table]
3Q `02 3Q `01 YTD 2002 YTD 2001
------ ------ -------- --------
INTEREST INCOME $(107.3) $(114.6) $(311.2) $(380.3)
INTEREST EXPENSE 99.9 121.8 292.7 355.2
EXCHANGE (GAINS)/LOSSES 8.3 1.5 10.9 (18.6)
MINORITY INTERESTS 59.1 72.3 169.7 218.3
AMORTIZATION OF GOODWILL AND INTANGIBLES 51.1 83.7 153.5 244.8
Other, net (40.5) (62.5) (104.0) (191.0)
------- ------- ------- -------
TOTAL $ 70.6 $ 102.2 $ 211.6 $ 228.4
------- ------- ------- -------
================================================================================
JOINT VENTURE SALES DETAIL
All sales reported here are end-market JV sales, presented on a "NET" basis,
rounded to the nearest $5 million.
[Download Table]
MERIAL 3Q `02 3Q `01 YTD 2002 YTD 2001
------ ------ ------ -------- --------
IVOMEC, HEARTGARD, other avermectins $130 $130 $ 350 $ 365
FRONTLINE 150 100 410 340
Biologicals 90 85 275 255
Other Animal Health 40 45 130 145
Poultry Genetics 55 50 165 155
---- ---- ------ ------
TOTAL MERIAL SALES $465 $410 $1,330 $1,260
---- ---- ------ ------
[Download Table]
AVENTIS PASTEUR-MSD 3Q `02 3Q `01 YTD 2002 YTD 2001
------ ------ ------ -------- --------
HEPATITIS VACCINES $ 20 $ 20 $ 50 $ 70
VIRAL VACCINES 10 10 25 35
Other Vaccines 175 125 325 265
---- ---- ------ ------
TOTAL AP-MSD SALES $205 $155 $ 400 $ 370
---- ---- ------ ------
================================================================================
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
[Download Table]
2002
MAIL RETAIL TOTAL
---- ------ -----
FIRST QUARTER 20 121 141
SECOND QUARTER 21 119 140
THIRD QUARTER 20 110 130
---- ---- ----
YEAR TO DATE 61 350 411
---- ---- ----
[Download Table]
2001
MAIL RETAIL TOTAL
---- ------ -----
FIRST QUARTER 18 120 138
SECOND QUARTER 18 115 133
THIRD QUARTER 19 110 129
---- ---- ----
YEAR TO DATE 55 345 400
---- ---- ----
Filing Submission - Alternative Formats (Word / Rich Text, HTML, Plain Text, SGML, XML, et al.)
Copyright © 2008 Fran Finnegan & Company All Rights Reserved.
www.secinfo.com
- Fri, 21 Nov 2008 05:48:22.1 GMT - Privacy - Help
